Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year 2024 Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025 Management to host earnings conference call on March 27 at 8:00... Read More

DENVER / Mar 26, 2025 / Business Wire / TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new Level II HCPCS code for the... Read More

DENVER / Mar 06, 2025 / Business Wire / TriSalus Life Sciences ® , Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences, which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that company researchers received two JVIR Top Paper Awards for a recent... Read More

HealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic Cancers DENVER / Feb 03, 2025 / Business Wire / TriSalus Life Sciences ® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its... Read More

DENVER / Feb 03, 2025 / Business Wire / TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced that it has requested a drawdown of $10 million under its previously announced $50 million credit agreement with... Read More

Q4 Revenue of approximately $8.3 million represents approximately 44% growth versus Q4 2023 Full year 2024 Revenue of approximately $29.4 million represent approximately 59% growth versus full year 2023 Q4 Operating Cash Flow of approximately ($5.6) million is a notable improvement compared to ($10.8) million in Q3 Company expects to achieve positive full year EBITDA in 2025 and positive Cash Flow during the second half of... Read More

DENVER / Jan 09, 2025 / Business Wire / TriSalus Life Sciences ® , Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, “Pressure Enabled Drug Delivery (PEDD) Significantly... Read More

Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 Launched TriNav ® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system’s full... Read More

DENVER / Nov 11, 2024 / Business Wire / TriSalus Life Sciences ® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy, nelitolimod, has announced a strategic partnership with Geo-Med, LLC (“Geo-Med”), a certified Service-Disabled Veteran-Owned Small... Read More

DENVER / Nov 07, 2024 / Business Wire / TriSalus Life Sciences ® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav ® LV Infusion System and TriGuide™ Guiding Catheter. These new devices are designed to optimize therapeutic delivery, enhancing treatment... Read More

Call Scheduled for Thursday, November 14, 2024, at 9:00 a.m. ET DENVER / Oct 31, 2024 / Business Wire / TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to... Read More

DENVER / Oct 14, 2024 / Business Wire / TriSalus Life Sciences ® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today that Mary Szela, Chief Executive Officer and President of TriSalus, will participate in a fireside chat at the 2024... Read More

DENVER / Sep 26, 2024 / Business Wire / TriSalus Life Sciences® Inc . (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional... Read More

Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (117%; p=0.004 and 39%; p=0.032) with lobar infusions and selective infusions, respectively DENVER / Sep 23, 2024 / Business Wire / TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with standard of care... Read More

Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods Reported gross margin of 88% in Q2 2024 and 86% for the six months ended June 30, 2024, compared to 83% and 81%, respectively, in the prior year periods Announces plan to launch the “DELIVER” Program in Q3 2024, clinical trials leveraging the TriNav® Infusion System... Read More

Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ET DENVER / Aug 01, 2024 / Business Wire / TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today it will host a conference call and webcast on August 15, 2024, at 9:00 a.m. ET to discuss financial results for... Read More

WESTMINSTER, Colo. / Jul 01, 2024 / Business Wire / TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the closing of its previously announced exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to... Read More

WESTMINSTER, Colo. / Jun 26, 2024 / Business Wire / TriSalus Life Sciences ® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the expiration and results of its previously announced exchange offer (the “Offer”) and consent solicitation (the “Consent... Read More

Hepatic arterial infusion (HAI) of nelitolimod has been well tolerated and associated with encouraging immunologic activity in patients with HCC and ICC 4 mg dose demonstrated 3 of 3 patients achieving disease control, with one complete response in the liver (5L ICC), one partial response (-31%), and one stable disease (SD) when combined with checkpoint inhibition Follow up of patients is ongoing to determine next steps in... Read More

DENVER / May 24, 2024 / Business Wire / TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its warrants (the... Read More

Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 Reported gross margin of 85% in 1Q24 Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion System growth initiatives Announced the appointment of Liselotte Hyveled to the Board of Directors Full year sales growth expected to exceed 50% Conference call May 15 th at 9:00 a.m. EDT DENVER / May 15, 2024 / Business Wire / TriSalus... Read More

Accomplished industry veteran brings deep strategic and operational expertise DENVER / May 07, 2024 / Business Wire / TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors. Ms. Hyveled brings over two... Read More

Call Scheduled for Wednesday, May 15, 2024, at 9:00 a.m. ET DENVER / May 06, 2024 / Business Wire / TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today it will host a conference call and webcast on May 15, 2024, at 9:00 a.m. ET to discuss financial results for the... Read More

$25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the achievement of certain revenue thresholds Capital from the transaction is expected to support execution of strategic expansion and fuel continued growth Including the full funding of this facility, along with current cash and cash equivalents on hand, the Company expects its cash runway to extend through 2025... Read More

Reported revenues of $5.7 million in 4Q23, up 77% over prior year Full year revenues of $18.5 million, up 49% over prior year Gross Margin of 90% in 4Q23 and 86% for full year CMS reimbursement granted for the TriNav® Infusion System via assignment of an HCPCS code Real-world data published on TriNav system demonstrating significant improvement in the delivery of therapeutics to liver tumors for patients with higher disease... Read More

New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery via retrograde venous delivery A retrospective clinical study of the Pressure-Enabled Drug Delivery™ (PEDD™) method supports selection of the TriNav® Infusion System for treatment-refractory hypovascular tumors DENVER & SALT LAKE CITY... Read More

DENVER / Mar 21, 2024 / Business Wire / TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that the Company will present data from recent research findings at the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, to be held March 23-28, 2024,... Read More

Q4 sales of approximately $5.7 million represent 77% growth versus 2022 Q4 and full year gross margin of approximately 90% and 86% respectively Full year 2024 sales growth expected to exceed 50% Conference call scheduled for Monday, April 1, 2024, at 9:00 a.m. ET DENVER / Mar 11, 2024 / Business Wire / TriSalus Life Sciences ® Inc. (Nasdaq: TLSI) announced today that the Company will host a conference call and webcast on... Read More

Nelitolimod, a class C TLR-9 agonist formerly called SD-101, is the Company’s therapeutic candidate designed to overcome biologic barriers in liver and pancreatic tumors Nelitolimod is currently being evaluated in three Phase 1/1b studies in adults with liver and pancreatic cancers in combination with TriSalus’ proprietary Pressure Enabled Drug Delivery™ technology DENVER / Mar 07, 2024 / Business Wire / TriSalus Life... Read More

Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, treatment refractory, and higher disease burden patients, further validating previous data in the real-world setting DENVER / Feb 29, 2024 / Business Wire / TriSalus Life Sciences ® Inc. (Nasdaq: TLSI), an oncology company integrating... Read More

Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11 th Reported 3Q23 revenues of $5.2 million in 3Q23, up 32% over prior year and nine-month year to date net revenues of $12.8 million, up 39% over prior year Favorable Phase 1 uveal melanoma PERIO-01 data demonstrating median progression free survival (PFS) of 11.7 months, with an 81% Disease Control Rate and 1 year overall... Read More

Call Scheduled for Tuesday, November 14, 2023, at 9:00 a.m. ET DENVER / Nov 07, 2023 / Business Wire / TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced it will host a conference call and webcast on November 14, 2023, at 9:00 a.m. ET to discuss financial results... Read More

New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier presentation from pancreatic adenocarcinoma trial Median Progression-Free Survival was 11.7 months, with an 81% Disease Control Rate with the optimal biologic dose of SD-101 (2 mg) in combination with... Read More

New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of a TLR9 agonist in pancreatic tumors DENVER & SAN DIEGO / Nov 03, 2023 / Business Wire / TriSalus Life Sciences® Inc. , (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors,... Read More

DENVER / Oct 25, 2023 / Business Wire / TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced it will present a variety of new data from its innovative clinical development pipeline at the Society for Immunotherapy of Cancer (SITC) 38 th Annual Meeting being held... Read More

Devlin Brings Significant Expertise in Commercialization, Sales and Marketing DENVER / Sep 06, 2023 / Business Wire / TriSalus Life Sciences® Inc. , (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that Jodi Devlin has joined the Company as President of TriSalus Therapeutics. In... Read More